Actuate 1902: Phase 1 2 Study of 9 ING 41, a Glycogen Synthase Kinase 3 Beta (GSK 3ß) Inhibitor, as a Single Agent or with Irinotecan, Temozolomide Irinotecan or Cyclophosphamide Topotecan in Pediatric Patients with Refractory Malignancies

Gender
Any

Age Group
Any

At a Glance

IRB#IRB20-0855

Lead PhysicianAmi Desai

Collaborator(s)N/A

EligibilityRecruiting